bioRxivImmunology
High neutralizing antibody levels against SARS-CoV-2 Omicron after UB-612 booster vaccination
F. Guirakhoo, S. Wang, C. Y. Wang, H.-K. Kuo, W.-J. Peng, H. Liu, L. Wang, M. Johnson, A. Hunt, M. M. Hu, T. P. Monath, A. Rumyantsev, D. Goldblatt
Abstract
The highly transmissible Omicron variant has caused high rates of breakthrough infections among vaccinated and convalescent individuals. Here, we demonstrate that a booster dose of UB-612 vaccine candidate delivered 7-9 months after primary vaccination increases neutralizing antibody levels by 131-, 61- and 49-fold against ancestral SARS-CoV-2, Omicron BA.1 and BA.2 variants, respectively. Based on the RBD protein binding antibody responses, we estimated a [~]95% efficacy against symptomatic COVID-19 caused by the ancestral strain after a UB-612 booster. Our results support UB-612 vaccine as a potent booster against current and emerging SARS-CoV-2 variants.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, beta, delta, and omicron variants
A. Banerjee, J. Lew, … D. Falzarano·bioRxiv·Jan 13, 2022
- SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster
S. Lusvarghi, S. D. Pollett, … C. D. Weiss·bioRxiv·Dec 22, 2021
- Homologous or Heterologous Booster of Inactivated Vaccine Reduces SARS-CoV-2 Omicron Variant Escape from Neutralizing Antibodies
- Durability of the Neutralizing Antibody Response to mRNA Booster Vaccination Against SARS-CoV-2 BA.2.12.1 and BA.4/5 Variants
P. QU, J. N. Faraone, … S.-L. Liu·bioRxiv·Jul 21, 2022
- Increased resistance of SARS-CoV-2 Omicron Variant to Neutralization by Vaccine-Elicited and Therapeutic Antibodies
T. Tada, H. Zhou, … N. R. Landau·bioRxiv·Dec 28, 2021
- Improved neutralization of the SARS-CoV-2 Omicron variant after Pfizer-BioNTech BNT162b2 COVID-19 vaccine boosting
K. Basile, R. J. Rockett, … J. Kok·bioRxiv·Dec 12, 2021